Hypothesis: Age‑related loss of cannabinoid receptor 1 (CB1) in the intestinal epithelium initiates a cascade that ages the gut microbiome, increases barrier permeability, and triggers vagal‑dependent neuroimmune signaling, thereby driving systemic inflammaging. Restoring epithelial CB1 reverses microbial senescence and lowers circulating inflammatory cytokines independently of neuronal CB1.

Mechanistic rationale

1. CB1 deficiency → barrier leak. In aging intestine, reduced CB1 elevates miR‑191‑5p and NF‑κB p65, directly suppressing ZO‑1 and occludin and raising paracellular flux [2]. This allows luminal microbial products (e.g., LPS, peptidoglycan) to reach the lamina propria.
2. Microbial product sensing → enterochromaffin cell activation. LPS‑TLR4 signaling in enterochromaffin cells boosts serotonin release, which stimulates vagal afferents. Chronic vagal firing alters nucleus tractus solitarius output, shifting the autonomic balance toward sympathetic dominance and promoting microglial priming in the brain.
3. Microbiome aging. Barrier leak exposes commensals to oxygen and inflammatory mediators, selecting for oxidative‑stress‑tolerant, proteobacteria‑rich communities. These microbes exhibit hallmarks of cellular senescence (increased β‑galactosidase activity, shortened telomeres, SASP‑like metabolite secretion) that we term “microbiome aging.” Such a community further amplifies LPS production, creating a feed‑forward loop.
4. Vagal mediation of systemic inflammation. Vagal afferents convey gut‑derived signals to the brain, where they stimulate central NF‑κB activation and cytokine release (IL‑6, IFN‑γ) that spill into circulation. Simultaneously, efferent vagal anti‑inflammatory signaling is weakened due to autonomic imbalance, reducing cholinergic inhibition of peripheral macrophages.
5. Reversibility. Pharmacologic CB1 agonism (ACEA) restores ZO‑1 expression and barrier integrity in senescent intestinal cells [2]. We predict that epithelial‑specific CB1 rescue in aged mice will normalize microbiome composition, reduce microbial senescence markers, lower serum LPS‑binding protein, and decrease plasma IFN‑γ/IL‑6 despite unchanged neuronal CB1 levels.

Testable predictions

• Group 1: Aged wild‑type mice (baseline).
• Group 2: Aged mice with intestinal‑epithelial‑specific CB1 knockout (expected exacerbation).
• Group 3: Aged mice treated with epithelial‑targeted CB1 agonist (ACEA) or gene‑therapy rescue.
• Group 4: Same as Group 3 plus subdiaphragmatic vagotomy (to test vagal dependence).

Measurements (at 3‑month intervals):

• Microbiome: 16S rRNA sequencing, diversity indices, quantification of senescence markers (β‑galactosidase activity in fecal lysates, telomere length via qPCR).
• Barrier function: FITC‑dextran plasma flux, immunofluorescence for ZO‑1/occludin.
• Vagal activity: heart‑rate variability, c‑Fos in nucleus tractus solitarius.
• Systemic inflammation: plasma IFN‑γ, IL‑6, IL‑1β, LPS‑binding protein.
• Neuroinflammation: Iba1 immunoreactivity and cytokine mRNA in hippocampus and hypothalamus.

Falsifiability: If epithelial CB1 restoration fails to (a) improve barrier integrity, (b) shift the microbiome toward a youthful profile, (c) reduce microbial senescence signatures, or (d) lower systemic cytokines—even when vagal signaling is intact—the hypothesis is refuted. Conversely, if vagotomy abolishes the anti‑inflammatory effect of CB1 rescue, it confirms the vagal‑mediated route.

This framework ties together the observed CB1‑ZO‑1 axis, microbiome aging, and neuroimmune communication, offering a concrete, falsifiable path to dissect whether the inflammaging signal originates in a dysbiotic, aged microbiome whose changes are gated by intestinal CB1 loss.